Overview : 遂に開始されたモノクローナル抗体による治療 [in Japanese] Monoclonal antibody therapy is beginning in the clinical setting.:Monoclonal antibody therapy is beginning in the clinical setting [in Japanese]
Access this Article
Search this Article
Kohler and Milstein demonstrated the “hybridoma technology” of producing MoAb capable of binding to tumor antigen with remarkable specificity and stability about 30 years ago. Many early trials using MoAbs revealed obstacles to successful therapy. Unfortunately, these trials did not establish MoAb therapy as the “magic bullet” as some had previously hoped. Treatment with murine MoAb induced human anti-mouse antibody (HAMA) responses. Once an immune response occurs, administered MoAb can be rapidly cleared from the circulation. Until recently, progress of MoAb treatment has been frustratingly slow for this obstacle. In the past five years, however, the situation has changed dramatically, with some MoAbs now showing clinical potential. The development of genetic engineering has pushed forward the clinical use of MoAbs. This technology has allowed the conversion of existing murine MoAbs into mouse-human chimeric MoAbs, and humanized MoAbs where only the MoAb conaplementarity-determining regions(CDR) are of murine MoAb. More recently, the production of fully humanized MoAb has been made routinely, using either phage technology or transgenic mice. MoAb therapy is beginning at last. Now, with the approval and widespread use of rituximab (Rituxan) for B-cell non Hodgkin's lymphoma and trastuzumab (Herceptin)for advanced breast cancer, MoAb therapy has significant success.
- Drug Delivery System
Drug Delivery System 17(1), 22-28, 2002-01-10
THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM